Role of Fibrocytes in the Bronchial Remodeling of Chronic Obstructive Pulmonary Disease
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 115
- 试验地点
- 2
- 主要终点
- Number of circulating blood fibrocytes
研究概览
简要总结
Chronic obstructive pulmonary disease (COPD) is a frequent airway disease characterized by both bronchial inflammation and remodelling.
Bronchial mucosa is infiltrated by macrophages, neutrophils and lymphocytes. In addition, the number of eosinophils can be also increased during exacerbation.
Airway remodelling is an abnormal tissue repair following bronchial inflammation, which contributes to none reversible pathological features, such as bronchial and peri-bronchial fibrosis. It also influences the prognosis of COPD and its mechanisms remain largely unknown. The role of fibrocytes has been demonstrated in the pathophysiology of asthma, lung fibrosis or pulmonary hypertension. However, the recruitment of blood fibrocytes and their involvement in COPD airway remodelling remain unknown.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients: diagnostic of Chronic obstructive pulmonary disease (COPD) exacerbation.
- •Control group: subjects without any history of lung disease and with normal lung function testing. Subjects will be separated in 2 sub-groups according to smoking history (Never smokers, smokers (former or current) and paired to patients according to age and sex.
- •Written informed consent
排除标准
- •Subject without any social security or health insurance
- •Asthma, lung fibrosis or idiopathic pulmonary hypertension
- •Chronic viral infections (hepatitis, HIV)
结局指标
主要结局
Number of circulating blood fibrocytes
时间窗: 2 months
Sampling of blood in Chronic obstructive pulmonary disease patients
次要结局
- Chemotactism of blood fibrocytes(Day 1 and at 2 months)
- Differenciation of blood fibrocytes(Day 1 and at 2 months)
- Number of exacerbation(12 months after V2)
- Annual decline of ventilatory function(12 months after V2)
- Mortality(12 months after V2)
- Characterization of fibrocytes(Day 1 and at 2 months)